TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study

Background and ObjectivesThis study aimed to compare the efficacy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S) to TACE plus lenvatinib (TACE-L) for the treatment of HCC with portal vein tumor thrombus (PVTT).MethodsThis cohort study recruited patients from September 2017 to Sept...

Descripció completa

Dades bibliogràfiques

Autors principals:	Biao Yang, Luo Jie, Ting Yang, Mingyang Chen, Yuemei Gao, Tian Zhang, Yuzu Zhang, Hao Wu, Zhengyin Liao
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2021-12-01
Col·lecció:	Frontiers in Oncology
Matèries:	hepatocellular carcinoma lenvatinib sorafenib portal vein thrombosis transcatheter arterial chemoembolization
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2021.821599/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!